Q-omics provides the consensus-scored CECR9 profile across patient tissues and cancer cell-line models. CECR9 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CECR9 is differentially expressed in 3, with the highest sampling consensus in CHOL. Additionally, CECR9 RNA expression shows 6,328 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, CHOL, and STAD as cancer lineages where CECR9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CECR9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CECR9 survival associations across molecular data types. CECR9 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CECR9 RNA expression–survival associations across cancer types. High CECR9 expression shows unfavorable associations in LUAD, COAD, THYM and UVM, but favorable associations in LIHC and BLCA. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CECR9 RNA expression.
This table summarizes CECR9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CECR9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CECR9 shows lower tumor expression in CHOL and higher tumor expression in LUSC and COAD. The CHOL box plot shows higher CECR9 RNA expression in normal versus tumor tissue (log2 FC = −0.323, t-test p = .032).
This table shows molecular features associated with CECR9 in patient tissues and cancer cell lines. In patient samples, CECR9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
